Leblanc T, Hillion J, Derré J, Le Coniat M, Baruchel A, Daniel M T, Berger R
Hématologie Pédiatrique, Hôpital Saint-Louis, Paris, France.
Leukemia. 1994 Oct;8(10):1646-8.
A child with acute myelomonocytic leukemia, bone marrow eosinophilia and inv(16) received first-line therapy including etoposide (VP-16). Cytopenia and monocytosis appeared 7 months after complete remission while the child was treated with maintenance chemotherapy. Blood abnormalities persisted after discontinuation of treatment. Nine months after complete remission, t(11;11)(q13;q23) and HRX rearrangement were detected. Five months later, overt leukemia of monocytic type occurred. The responsibility of VP-16 therapy in this treatment-related acute myelocytic leukemia is discussed.
一名患有急性粒单核细胞白血病、骨髓嗜酸性粒细胞增多和16号染色体倒位的儿童接受了包括依托泊苷（VP - 16）在内的一线治疗。完全缓解7个月后，该儿童在接受维持化疗时出现血细胞减少和单核细胞增多。停止治疗后血液异常仍持续存在。完全缓解9个月后，检测到t(11;11)(q13;q23)和HRX重排。5个月后，发生了明显的单核细胞型白血病。本文讨论了VP - 16治疗在这种与治疗相关的急性髓细胞白血病中的作用。
